Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Acquired by EntryPoint Capital LLC

EntryPoint Capital LLC increased its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 101.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 69,526 shares of the company’s stock after purchasing an additional 34,982 shares during the period. EntryPoint Capital LLC’s holdings in Olema Pharmaceuticals were worth $405,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Intech Investment Management LLC acquired a new position in shares of Olema Pharmaceuticals during the third quarter worth $163,000. Charles Schwab Investment Management Inc. increased its stake in Olema Pharmaceuticals by 168.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company’s stock worth $3,949,000 after buying an additional 207,565 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Olema Pharmaceuticals in the 3rd quarter worth $238,000. Great Point Partners LLC boosted its position in Olema Pharmaceuticals by 25.5% in the 3rd quarter. Great Point Partners LLC now owns 1,000,000 shares of the company’s stock valued at $11,940,000 after buying an additional 203,120 shares during the last quarter. Finally, Portland Investment Counsel Inc. purchased a new stake in shares of Olema Pharmaceuticals during the third quarter worth about $143,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Insider Buying and Selling at Olema Pharmaceuticals

In related news, major shareholder Bain Capital Life Sciences Inv bought 300,000 shares of the stock in a transaction dated Wednesday, January 8th. The stock was bought at an average cost of $5.76 per share, with a total value of $1,728,000.00. Following the completion of the acquisition, the insider now owns 7,800,000 shares of the company’s stock, valued at $44,928,000. This trade represents a 4.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 19.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

OLMA has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th. Oppenheimer reiterated an “outperform” rating and set a $25.00 target price (down from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th.

Olema Pharmaceuticals Stock Performance

NASDAQ:OLMA opened at $4.19 on Wednesday. The company has a market capitalization of $286.32 million, a price-to-earnings ratio of -1.91 and a beta of 2.11. Olema Pharmaceuticals, Inc. has a one year low of $3.94 and a one year high of $16.62. The stock has a 50-day simple moving average of $5.06 and a 200 day simple moving average of $8.20.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.12. On average, equities research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.